Evidence map›Paper›PMID 11850840›Full record

ArticleOncogene2002

Facilitation of adenoviral wild-type p53-induced apoptotic cell death by overexpression of p33(ING1) in T.Tn human esophageal carcinoma cells.

Hideaki Shimada, Tian-Ling Liu, Takenori Ochiai, Takanori Shimizu, Ygal Haupt, Hirofumi Hamada, Toshihiro Abe, Masaaki Oka, Masaki Takiguchi, Takaki Hiwasa

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. INGs are potential drug targets for cancer.Journal of cancer research and clinical oncology · 2017
    Review
  4. Article
  5. Ectopic expression of p33Oncology letters · 2015
    Article
  6. Article
  7. ING1 and ING2: multifaceted tumor suppressor genes.Cellular and molecular life sciences : CMLS · 2013
    Review
  8. Article
  9. Article
  10. Article
  11. Inhibitor of growth tumor suppressors in cancer progression.Cellular and molecular life sciences : CMLS · 2010
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. p53 gene therapy for esophageal cancer.Journal of gastroenterology · 2002
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Hideaki ShimadaDepartment of Academic Surgery, Chiba University, Graduate School of Medicine, Inohana 1-8-1, Chuo-ku, Chiba 260-8670, Japan.
Tian-Ling Liu
Takenori Ochiai
Takanori Shimizu
Ygal Haupt
Hirofumi Hamada
Toshihiro Abe
Masaaki Oka
Masaki Takiguchi
Takaki Hiwasa
Chiba University · JPYamaguchi University · JPSapporo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To investigate the effect of p33(ING1) on wild-type p53 gene therapy, T.Tn human esophageal carcinoma cells were stably transfected with p33(ING1) cDNA. Infection with Ad-p53 (recombinant adenovirus containing wild-type p53) into p33-transfected cells reduced cell viability, while infection with empty vector had little effect. This reduced viability was shown to be due to apoptotic cell death by the TUNEL (terminal deoxynucleotidyl transferase-mediated nick end-labeling) assay. Following infection with Ad-p53, levels of p53 were similar in p33-expressing cells and in the parental line. However, levels of p21 and Mdm2 were elevated in p33-transfected cells. Nonetheless, this enhanced expression of Mdm2 appeared to be ineffective in downregulating p53. Transient transfection with mutant Mdm2 prior to Ad-p53 infection provided a significant protection as compared with cells transfected with wild-type Mdm2. These results imply a synergistic effect between p33 and p53 in the induction of apoptosis of human esophageal carcinoma cells. A role for Mdm2 in this synergism is suggested.

Indexed as

ApoptosisNuclear ProteinsAdenoviridaeBlotting, WesternCell AdhesionCell Cycle ProteinsCell DivisionCell SurvivalContact InhibitionDNA-Binding ProteinsEsophageal NeoplasmsGenes, p53Genes, Tumor SuppressorGenetic TherapyGenetic VectorsHumansCell Cycle ProteinsDNA-Binding ProteinsING1 protein, humanInhibitor of Growth Protein 1Intracellular Signaling Peptides and ProteinsMDM2 protein, humanNuclear ProteinsProteinsProto-Oncogene ProteinsProto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53Tumor Suppressor Proteins

Identifiers

PMID11850840
OpenAlexW2332286545

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.